Press Releases Oncolys BioPharma Inc.

Equities

4588

JP3202170001

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-02 am EDT			5-day change	1st Jan Change
706 ^JPY	-0.56%		+1.15%	+24.51%

Feb. 09	Oncolys BioPharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 07	Medigen Biotechnology Corp. Announces Signing of the Sales Cooperation Agreement for the New Drug OBP-301 in Japan	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oncolys BioPharma : Announcement of Investigator-Initiated Phase 2 Clinical Trial Agreement For Immunotherapy refractory Esophagogastric adenocarcinoma	Dec. 19	PU
Oncolys BioPharma : Achievement of Primary Endpoint for Efficacy in the Phase2 Clinical Trial for Telomelysin-Radiation Combination Therapy	23-10-16	PU
ASCO 2023 ANNOUNCEMENT: Encouraging Preliminary Data of OBP-301 with Pembrolizumab in refractory gastroesophageal adenocarcinoma	23-06-06	PU
Oncolys BioPharma : Non-consolidated Financial Results for the Three Months Ended March 31, 2023	23-05-12	PU
Oncolys BioPharma : Non-consolidated Financial Results for the Nine Months Ended September 30, 2022	22-11-04	PU
Oncolys BioPharma : Announcement of Completion of Enrollment in Phase IIa Clinical Trial of OBP-601 (censavudine, TPN-101) in Patients with Progressive Supranuclear Pals	22-08-17	PU
Oncolys BioPharma : Non-consolidated Financial Results for the Six Months Ended June 30, 2022	22-08-05	PU
Oncolys BioPharma : Non-consolidated Financial Results for the Fiscal Year Ended December 31, 2021	22-02-10	PU
Oncolys BioPharma : Announcement of Enrollment of First Patient in Phase IIa study for OBP-601 (Censavudine, TPN-101) in patients with ALS and/or FTD	22-01-21	PU
Oncolys BioPharma : First Patient Dosed in NRG Oncology Phase I Clinical Trial for Telomelysin(OBP-301)-Chemoradiation Combination Therapy for Esophageal Cancer Patients	21-12-07	PU
Oncolys BioPharma : Announcement of Enrollment of First Patient in Phase IIa Clinical Trial of OBP-601 (Censavudine, TPN-101) in Patients with PSP	21-11-18	PU
Non-consolidated Financial Results for the Nine Months Ended September 30, 2021 [Japanese GAAP]	21-11-05	PU
Oncolys BioPharma : Announcement of FDA Clearance of Two IND Applications to Initiate Phase 2 Clinical Trials of OBP-601 (Censavudine, TPN-101)	21-08-15	PU
Oncolys BioPharma : to partner with Thermo Fisher Scientific for viral vector development and GMP manufacturing of their proprietary oncolytic virus, OBP-301	21-08-04	PU
Oncolys BioPharma : Announcement of the effect of OBP-2011 against Indian and South African variants of SARS-CoV-2 virus	21-07-26	PU
Oncolys BioPharma : Announcement of manufacturing partnership on OBP-2011, an investigational product for COVID-19	21-07-19	PU
Oncolys BioPharma : Announcement of the effect of OBP-2011 against SARS and MERS	21-06-28	PU
Oncolys BioPharma : Non-consolidated Financial Results for the Three Months Ended March 31, 2021	21-05-07	PU
Oncolys BioPharma : Announcement of First Patient Enrolled in Oncology Investigator-Initiated Phase 2 Clinical Trial for Telomelysin (OBP-301) of Head and Neck Cancer	21-05-06	PU
Oncolys BioPharma : Announcement of the effect of OBP-2011 against coronavirus variant	21-03-31	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Oncolys BioPharma Inc.

Equities

4588

JP3202170001

Press Releases

Filters